SCT510A

DRUG2 trials

Sponsors

Sinocelltech Ltd.

Conditions

Wet Age-related Macular Degeneration

Phase 1

The Study of Drug SCT510A in Patients With Wet Age-related Macular Degeneration (wAMD)

Sinocelltech Ltd.Wet Age-related Macular Degeneration

Start: 2020-11-06End: 2022-10-31Target: 66Updated: 2020-09-25

Phase 3

This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD

Sinocelltech Ltd.Wet Age-related Macular Degeneration

Start: 2023-02-14End: 2025-08-31Target: 446Updated: 2023-02-16